![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-equity-security-100.png)
VistaGen Therapeutics
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders.
![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-administrator-male-100.png)
Shawn K. Singh
CEO & Director
VistaGen Therapeutics
CEO & Director
VistaGen Therapeutics
Shawn Singh has has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles.